ABSTRACT. Ethidium homodimer (EHD) was conjugated to B72.3 monoclonal antibody using a method whereby 85-90% of the conjugated EHD remains available for DNA intercalation. Antibody was thiopropionylated by reaction with N-succinimidyl 3-(2-pyridyldithio)propionate and reduction of pyridyldithio groups with dithiothreitol. EHD was maleimido-functionalized with succinimidyl-4-(N-maleimidoethyl)-cyclohexane-1-carboxylate and treated with thiopropionylated antibody to obtain a conjugate containing ϳ3.4 EHD per antibody molecule. For biologic studies, 14 C-labeled EHD was synthesized by reductive amination and conjugated as above. In vitro the conjugate maintained chemical integrity and immunoreactivity, while in vivo its targeting of LS174T tumors was reduced compared with that of iodinated antibody. A decrease in isoelectric point of the immunoconjugate was also observed. NUCL MED BIOL 25;3:267-278, 1998.
INTRODUCTION
Immunoconjugates of monoclonal antibodies (MAbs) with drugs (15) (16) (17) (18) , toxins (1, 6) and radionuclides (8, 14) have gained considerable attention for the treatment of human cancers. The underlying concept is the use of MAbs with their remarkable specificity and selectivity in targeting tumors as carriers of the intended probes to desired sites. The anticipation that such targeting will enhance tumor cell killing while minimizing damage to normal tissues has been shown to be true for various antibody conjugates, including those containing DNA-binding agents such as adriamycin, doxorubicin (17) and vindesine (15, 18) .
In addition to the role antibodies play as agents that enhance targeting, many of them are internalized by tumor cells. Consequently, if such antibodies are conjugated to toxic molecules to which the plasma membrane is impermeable, they can be used to bring into the cell agents that are otherwise excluded. Such an approach would enable the assessment of the therapeutic potential of such molecules.
To this end, we have conjugated to the B72.3 MAb the DNA intercalator ethidium homodimer (EHD), a molecule that cannot permeate mammalian cell membranes. Although Wagner et al. (20) developed a method for chemically conjugating EHD through its carbohydrate moiety to proteins such as transferrin, their results showed that the conjugate-bound EHD did not intercalate with DNA, presumably owing to some inadvertent chemical change. In the conjugation approach presented here, the protein-bound EHD molecules retain their ability to intercalate with DNA. However, our data reveal that, although the immunoreactivity and the DNA-binding ability of the B72.3(EHD) 3 immunoconjugate were preserved, its ability to target tumors declined substantially and that this appears to have been caused by an inadvertent change in its isoelectric point (pI).
MATERIALS AND METHODS

General
Ethidium homodimer (EHD-I), N-succinimidyl 3-(2-pyridyldithio)-propionate (SPDP) and N-succinimidyl 4-(N-maleimidoethyl)cyclohexane-1-carboxylate (SMCC) were obtained from Molecular Probes (Eugene, OR). All other chemicals were purchased from Aldrich Chemical Company (Milwaukee, WI). [ 14 C]Formaldehyde at a specific activity of 54 mCi/mmol was obtained from NEN Research Products, DuPont Company (Boston, MA). High performance liquid chromatographic (HPLC) analyses were carried out on a Waters 510 HPLC system (Milford, MA) equipped with a tuneable UV detector. Autogamma 500 (Packard Instruments, Downers Grove, IL) and LS 8000 (Beckman Instruments, Irvine, CA) instruments were used for counting all radioactive samples. Thin-layer chromatographic (TLC) analyses of EHD and its derivatives were carried out on silica plates (mobile phase, n-butanol: trifluoroacetic acid:water:acetonitrile:ethyl acetate, 8:0.5:1:16:20).
Incorporated, Ann Arbor, MI) with PBS as the mobile phase. The presence of Ն98% radioactivity at the origin indicated the purity of this radiochemical. The specific activity of 2.5 Ci/g of IgG corresponded to an 125 I:IgG ratio of 1:6.
IMMUNOASSAY. Since B72.3 is known to react strongly with bovine submaxillary mucin (BSM), the immunoreactivity of the 125 I-B72.3 was assessed in 96-well microtiter plates (Costar, Cambridge, MA) coated with 1 g BSM (4). In brief, serial dilutions of 125 I-B72.3 (15 g, 7.5 g, etc.), prepared in 0.1 M PBS containing 1% BSA and 0.1% Tween 80, were added to each well and the plates were incubated at 37°C for 1 h. The plates were then washed five times with PBS in a plate washer (model 1250 Immunowash, Bio-Rad Laboratories, Incorporated, Hercules, CA), and the radioactivity associated with each well was counted on a ␥-counter. The data were analyzed and are presented as a scatchard plot (Fig. 2) . (Fig. 3) . After 30 min at room temperature (RT), 200 L of bicarbonate buffer (0.1 M bicarbonate, 0.5 M NaCl, pH 8.3), 63 L of aqueous sodium cyanoborohydride (10 mg/mL, 3.4 mol) and 200 L of methanol were added. The tightly closed vial was kept at RT for 48 h and monitored by radio-ITLC in PBS, wherein free formaldehyde and its oxidation products move with the solvent front and EHD remains at the origin. The product (52% yield) was purified by preparative ITLC in PBS. The strip containing EHD was eluted with n-butanol:trifluoroacetic acid: water:methyl cyanide:ethyl acetate (8:1:1:16:20) and evaporated to dryness by nitrogen purge. Three coevaporations with dry acetonitrile ensured the product in pure form, free of any organics and moisture.
Synthesis of [N-Methyl
Formation and Characterization of the EHD-B72.3 Conjugate
SYNTHESIS. 2 A gently stirred solution of 16 mg of B72.3 in 4 mL of PBS was treated with slow addition of 1 mg of SPDP in 150 L of ethanol at RT for 40 min (Fig. 4) ; unreacted SPDP was removed by gel filtration on a PD-10 column, and the eluate was concentrated on a Centricon-30. To determine the number of conjugated 2-pyridyl disulfide groups (3), we subjected the immunoconjugate to a buffer exchange with 0.1 M sodium acetate buffer, pH 4.4, containing 0.1 M NaCl using Centricon-30.
To a portion of diluted protein solution at RT, 100 L of 50 mM dithiothreitol (DTT) was added, and absorption at 343 nm and 280 nm was assessed on a UV-VIS spectrophotometer after 30 min. Based on the observed OD 343 of the solution and the molar absorptivity of 2-thiopyridone (2-PT)ε 343 ϭ 8080, the concentration of 2-PT released by DTT reduction from the MAb was obtained. Knowing the ε 280 of 2-PT (5100), the OD 280 of the protein ϭ total OD 280 Ϫ [concentration 2-PT ϫ 5100]. To the main stock, 10 mg of DTT was added and incubated for 45 min at RT. The thiolated antibody was purified on a PD-10 column pre-equilibrated with PBS, and the protein eluates were concentrated (vide infra) and stored under argon.
To 1 mg of EHD (1.17 mol), a solution of one equivalent (0.143 mg, 1.17 mol) of 4-dimethylaminopyridine (DMAP) in 25 L of dry dimethylformamide (DMF) was added. The mixture was vortexed and SMCC (0.39 mg, 1.17 mol) in 25 L of dry DMF was added, the vial tightly capped and vortexed again, and the sample was incubated in the dark at RT overnight. TLC analysis revealed a sharp spot (R f ϭ 0.41) above the EHD spot (R f ϭ 0.34) that accounted for more than 85% of the fluorescence absorption. PBS (1 mL) was added, and the solution was extracted with ethyl acetate (3 ϫ 1 mL) to remove unreacted SMCC and DMAP. The EHD-containing aqueous phase was purged with argon and added to the thiopropionylated MAb solution in PBS (pH 7.4) under argon. The mixture was gently vortex-mixed and incubated in the dark at RT overnight; 2 mg of N-ethylmaleimide in 50 L of DMF was then added and the mixture was incubated for 1 h. Dialysis against PBS (3 ϫ 0.5 L) resulted in a bright-red clear solution. Based on the ε 490 of EHD (8.34 ) and the observed OD 490 for the conjugate, the concentration of bound EHD was determined. Knowing the ε 280 of EHD (66.94), we calculated its contribution to the absorptivity at OD 280 . Based on the OD 280 for protein alone, the protein concentration could also be computed. Routinely three to four EHD molecules were conjugated per molecule of protein. construction of a radio-HPLC profile, the eluates from 14 C-labeled immunoconjugate were collected every minute and the activity counted in a scintillation counter using Aquasol (20 mL).
ASSESSMENT OF IMMUNOREACTIVITY OF B72.3(EHD) 3 BY INDIRECT
RADIOIMMUNOASSAY. The procedure of Carney et al. (4) developed for ELISA was adapted with some modifications for radioimmunoassay (RIA). The BSM-coated plates were prepared as described above. Stock solutions of B72.3 and B72.3(EHD) 3 were prepared at 10 g/mL and were serially diluted down to 0.1 g/mL in PBS containing 1% BSA and 0.1% Tween 80. A 100-L aliquot of the antibody solution was added, and the plates were incubated at 37°C for 1 h and then washed five times with PBS in a microplate washer. 125 I-rabbit antimouse IgG (NEN Research Products, ϳ150,000 cpm/100 L/well) prepared in the same dilution buffer was added, the plates were incubated for 1 h at 37°C and washed five times with PBS in the plate washer before counting.
Determination of pI of MAb by Isoelectric Focusing
The electrophoretic mobilities of proteins were determined in an isoelectric focusing chamber (EC-Apparatus Corporation, St. Petersburg, FL) equipped with a thermal control unit. The samples were focused on a 1% agarose focusing gel (pI 3-10; Iso-Gel, FMC Bioproducts, Rockland, ME) that was prefocused for 10 min at 15°C at a constant voltage (500 V) with the current and power set at 20 mA and 10 W, respectively. The samples (15 g/10 L) were loaded at the cathode pole (1 M NaOH) along with pI markers (FMC Bioproducts, Rockland, ME). After focusing at 15°C for 90 min, the gels were fixed for 20 min in a solution containing 18 g of sulfosalicylic acid, 30 g of trichloroacetic acid and 180 mL of methanol diluted to 500 mL with water and then dried, washed and stained with Coomassie brilliant blue R-250.
Preparation of LS174T Tumor-Bearing Mice
All experiments were carried out in compliance with the National Institutes of Health standards and the Public Health Service policy on the use of laboratory animals. Human colonic adenocarcinoma LS174T cells (#F-11130, ATCC) were maintained as monolayers in Dulbecco's modified Eagle's medium (GIBCO BRL, Life Technologies, Grand Island, NY) containing 10% fetal bovine serum (50 mL total) and enriched with 100 M minimum nonessential amino acids, 2 mM L-glutamine and 50,000 U/L of penicillin-streptomycin. The cell cultures were passaged twice a week. To provide single-cell suspensions for injection, the cells were gently pipetted and repeatedly passed through a syringe with a 22-gauge needle. Athymic nu/nu female mice 4 -5 weeks old (Harlan Sprague Dawley, Indianapolis, IN) were injected subcutaneously in the flank 
PHARMACOKINETICS.
For pharmacokinetic experiments mice received an intravenous injection (lateral tail vein) of 10 -20 g of the labeled antibody and were sacrificed between 1 min and 5 days later. The tissue activity was counted in either a ␥-counter or a liquid scintillation counter. Based on the fractional tissue activity, the percent activity per organ and the tumor-to-nontumor (T/NT) ratios were determined.
SAMPLE PREPARATION FOR LIQUID SCINTILLATION COUNTING.
A reliable and reproducible method of sample preparation and quench correction for the loss in counting efficiency was needed. Scintillation vials with plastic cap-liners were used. The tissue samples were rinsed with water and blotted, and each was placed in a vial (20-mL capacity) and weighed. Following the addition of NCS-II (Amersham Corporation, Arlington Height, IL; 1 mL/0.1 g tissue), the vials were incubated overnight on an orbital shaker at 37°C until the solution cleared. A freshly prepared solution of benzoyl peroxide in toluene (1 g/5 mL; 0.3 mL/mL of NCS-II used) was added and the samples vortex-mixed and kept at 45°C for 1 h until discoloration was completed. To maximize counting efficiency and minimize background, the samples were neutralized with glacial acetic acid (30 L/mL of NCS-II used), BCS-NA (Amersham, 15 mL) was added and, to prevent any phase separation, Tween 80 (0.1-1 mL/vial) was added prior to determining radioactive contents in a liquid scintillation counter. Quench correction was carried out by constructing a calibration curve (counting efficiency versus added counts per minute) after spiking each sample with a known amount of 3 H.
RESULTS
In a typical HPLC profile (UV 280 ) of ascites (Fig. 1A) , two major peaks with molecular weights corresponding to IgG (150 kDa, 19. profile (Fig. 1B) demonstrates the presence of a single 150 kDa molecular weight species (19.2 min). Its immunoaffinity is evident from the Scatchard analysis ( Fig. 2 ; K a ϭ 1.4 ϫ 10 10 M Ϫ1 ) of its binding to antigen BSM and is somewhat higher than the value reported using LS174T antigen TAG-72 (10, 11) .
In the synthesis of [N-methyl- 14 C]EHD from [ 14 C]formaldehyde by reductive amination (Fig. 3) , if the Schiff-base form of EHD is not protected by conversion to its pseudobase, a tetrahydro-Nmethyl EHD is formed as evidenced by the change in fluorescence from red to blue (reaction I). However, reacting the pseudobase of EHD with formaldehyde prior to its back conversion to the Schiff-base form (reaction II) bypasses this problem. The labeling resulted in a specific activity of 13.5 mCi/mmol from [ 14 C]HCHO (54 mCi/mmol), indicating that, on average, approximately two molecules of formaldehyde had reacted per molecule of EHD. Radio-TLC showed a single highly fluorescent spot (R f ϭ 0.34) that accounted for Ͼ98% of the 14 C activity. In the procedure for conjugation of EHD to B72.3 (Fig. 4) , the thiol groups were introduced by the method of Carlsson et al. (3) using SPDP, a heterobifunctional cross-linking agent that reacts with ε-amino groups of lysine residues in a nonsite-specific manner. Pyridyldithio groups thus introduced (6 -8/IgG) were reduced with DTT at pH 4.4 (acetate-EDTA) wherein only the extrinsic disulfides were prone to reduction. EHD was made thiol-reactive by the introduction of maleimide groups upon reaction with the heterobifunctional agent SMCC. The thiolated antibody reacted with this chemical in oxygen-free PBS (RT, overnight, argon) yielding a conjugate containing three to four EHD molecules. In the same manner [N-methyl- 14 C]EHD was conjugated to B72.3. In the size-exclusion HPLC (UV/radio) of this radioimmunoconjugate (Fig. 5) , a small shoulder at the base prior to the IgG peak may be seen because of the dimeric aggregate (ϳ10 -15%) formed during conjugation. Chemical and radiochemical homogeneity of the preparation are confirmed by the observation that all injected activity was accounted for in the IgG peak. A plot of calibration of the HPLC column with various protein standards revealed a good correlation between protein molecular weights and retention times (data not shown). The specific activity of the immunoconjugate was 353.8 mCi/mmol; a 3-fold increase from 113.5 mCi/mmol for [N-methyl- 14 C]EHD is consistent with the conjugation ratio of 3:1 determined by spectrophotometry. Based on fluorescence titration studies, the ability of protein-bound EHD to intercalate DNA was found to be nearly 90% (data not shown). RIA of B72.3(EHD) 3 ( Fig. 6) indicates that conjugation of three to four EHD per B72.3 molecule by the SPDP-SMCC method had no effect on its immunoreactivity. The isoelectric focusing data (Fig. 7) show that the native antibody consists of three close moving isoforms (pIs of 7.0, 7.1 and 7.2) with a midpoint pI of 7.1 (lanes 1 and 3) . The conjugate (lane 4), on the other hand, has a profile that contains several isoforms of decreased pI from 5.9 to 7.0 (midpoint pI 6.4). The pI of these antibody preparations was deduced from the calibration plot of the pI of the standard markers versus the distance traveled from the cathode (Fig. 8) . The marker proteins resolved into distinct bands representing the proteins of varying electrophoretic mobilities (Fig. 7, lanes 2 and 5; pI range 3.6 -10.2), and diluting the markers in 10 L of PBS (equaling that for the antibody samples) did not affect their mobilities (lane 5).
The tumor uptake of 125 I-B72.3 ( Fig. 9 ) increased with time, reaching 28 -30% of injected dose per gram organ (ID/g) by 24 h, and the activity remained close to these levels thereafter. The radioactivity was not retained in normal tissues and maximum tumor-to-nontumor ratios were seen at 72 h. However, the biodistribution profile of B72.3[ 14 C-EHD] 3 ( Fig. 10A ) reveals a tumor uptake of 7-9% by 12 h that remained steady. This is nearly 3-to-3.5-fold less than the uptake of unconjugated 125 I-B72.3. Concurrently, a high percentage of activity was found in the liver (40 -60% ID/g), spleen (10 -15% ID/g), and kidneys (5-8% ID/g). The radiolabeled 125 I-B72.3(EHD) 3 shows a similar profile (Fig.   10B ) in that tumor activity gradually rose to 8 -9% and remained unchanged thereafter. However, its localization within the liver by 1 h (ϳ20% ID/g) was nearly 2.5-fold less than that of the [ 14 C-EHD]-labeled MAb, and this activity declined thereafter. A concurrent rise of activity in the thyroid was also noted with time.
The blood pharmacokinetics of all three agents are summarized in Table 1 . While the blood clearance of all preparations was biphasic, the clearance of conjugates was nearly twice as rapid as that of the native antibody. (2, 7, 12) was reductively methylated to ethidium homodimer (Fig. 3) . Initially labeling at pH 5-6 resulted in a change of the native fluorescence from red to blue, and the silica TLC analysis showed that compared to the R f of EHD (0.55), the newly formed product had a much higher value of 0.8. Although primary amines are converted into secondary amines during reductive amination, this is not likely to modify the fluorescence properties of EHD. The change in color meant the native chromophore had been modified. The two ring nitrogens in the form of cyclic Schiff bases (i.e., C ϭ N ϩ R 1 R 2 ), an essential part of the chromophore, may have been reduced inadvertently during reductive amination with cyanoborohydride, and this may have led to the fluorescence color change. To avoid this, the vulnerable chromophore was converted to its pseudobase form under alkaline conditions, reductive amination was carried out, and the original red fluorescence was regenerated by acidification. A radiochemical yield of ϳ52% and purity of Ն98% were achieved following purification by preparative ITLC. In essence, a facile and mild method of labeling EHD with 14 C has been developed. In our early attempts to conjugate EHD to B72.3, the maleimidofunctionalization of EHD was carried out in PBS using stoichiometric amounts of SMCC. The isolated yield of the immunoconjugate was only ϳ25%, the remaining being aggregated protein. Realizing that this was due to the lack of solubility of SMCC in aqueous buffers, we then carried out the reaction of EHD with SMCC in DMF, and any unreacted SMCC was extracted out of the solution with ethyl acetate before adding the maleimido-functionalized EHD to the thiopropionylated antibody. This modification improved the yield of immunoconjugate to 60% and emphasizes the need to avoid formation of aggregates associated with the use of SMCC in aqueous solutions.
The biodistribution results of 125 I-B72.3 and B72.3[ 14 C-EHD] 3 immunoconjugate indicate that while the immunoreactivity of the EHD conjugate was similar to the native iodinated MAb (Fig. 6) , its tumor uptake was 3-to 3.5-fold less (7-9% versus 28 -30% ID/g). Since the injected activity was recovered in the IgG peak (Fig. 5) , this decrease is not due to aggregation of the conjugate as demonstrated by the size-exclusion HPLC analysis of the conjugates. Interestingly, our earlier work (19) had demonstrated that while the radioiodination of the anti-insulinoma MAb A1D2 at iodine: protein ratios of 15:1 and 25:1 minimally affected in vitro immunoreactivity assessed by RIA, it nevertheless led to an ϳ3-fold reduction in tumor uptake in vivo; in fact, the higher the iodine: MAb ratio, the lower the tumor uptake. It is clear, therefore, that such in vitro testing of immunoconjugates does not necessarily predict their in vivo behavior. Other investigators have also reported such discrepancies between in vitro immunoassay and in vivo biodistribution results. For example, Sakahara et al. (13) , assessing the in vitro affinity of two MAb undergoing identical labeling procedures and of the same MAb radiolabeled with two different isotopes, found that the data did not reflect the in vivo behavior of these conjugates. Rodwell et al. (9) compared the in vivo behavior of R9.75 MAb iodinated by either conventional tyrosine-directed electrophilic labeling or an iodinated tyrosine-containing peptide site-specifically attached to the oxidized oligosaccharides present on the F c region of the antibody. In these studies, the site-specifically radiolabeled antibody localized in tumors with an 18-fold greater efficiency than the corresponding conjugate modified nonselectively on its tyrosines, despite the fact that in vitro both radioimmunoconjugates had comparable binding properties with the antigen.
To address whether this difference in tumor uptake was a consequence of the dissociation of the 14 C label, biodistribution experiments were also performed using an 125 I-B72.3(EHD) 3 conjugate. A low tumor uptake (8.5% ID/g) corroborated the above results. Interestingly, the liver uptake of 125 I-B72.3(EHD) 3 was not so high as that seen with [ 14 C-EHD]-labeled immunoconjugate. However, since high radioactivity ( 125 I) was seen in the neck contents and urine, presumably owing to free iodide, the data seem to indicate that while both immunoconjugates were rapidly taken up and retained by the liver, the radioiodine became dissociated from its immunoconjugate (probably by the action of various liver dehalogenases) and was then either excreted or taken up by the thyroid. This argument is supported by various studies demonstrating that the tyrosine-directed iodination of MAb usually leads to in vivo deiodination and, therefore, a high thyroid activity. For example, using 125 I-81C6 MAb in tumor (D-54 MG)-xenografted nude mice, Zalutsky et al. (21) reported that the antibody directly iodinated by Iodogen resulted in high thyroid uptake and increased urinary excretion of radioiodine as compared to the same antibody labeled with a small radioiodinated molecule. It is probable that such in vivo deiodination is due to the structural similarity between the iodotyrosines created in conventional protein iodinations and thyroid hormones, compounds known to undergo extensive enzymatic dehalogenation (5) .
Since the biodistribution experiments (Figs. 9 and 10) demonstrate a significant reduction in the tumor-targeting capacity of the B72.3(EHD) 3 that was due to neither alteration in the immunoreactivity nor molecular weight changes of MAb (Figs. 5 and 6 ), the pIs of these immunoconjugates were assessed. The midpoint pI of the native B72.3 MAb decreased from 7.1 to 6.4 following EHD conjugation (Figs. 7 and 8 ). The conjugate also showed a series of closely related bands, indicating a heterogeneity associated with the formation of several isoforms during such lysine-directed conjugation. Such a decrease in pIs could indicate either the acquisition of negative charges by the antibody or the neutralization of its native positive charges during the following three phases of conjugation.
(1) SPDP-antibody conjugate. Since the SPDP-SMCC-based conjugation method directs the EHD molecules to the ε-amino groups of the lysine residues on the antibody, these amino groups will be converted into amides, and for every SPDP molecule conjugated, one positive charge will be neutralized. In our studies, six to eight SPDP molecules were conjugated on average per MAb molecule during its thiopropionylation and, consequently, six to eight lysyl residues were neutralized, an overall loss of six to eight positive charges. (2) The EHD molecule. Only one of the eight nitrogen atoms in this molecule was used in its conjugation to the antibody. Thus, the MAb can potentially carry seven positive charges per conjugated EHD molecule. However, the pK a of the amino groups of EHD differ greatly and, as such, all of them will not be positively charged at physiologic pH. For example, the pK a of the four aromatic amino groups is ϳ4.6, and at pH 7.4 they will lose a proton and hence their positive charge. In addition, the two nitrogen atoms within the phenanthridine rings of EHD in the form of Schiff bases, each carrying a single positive charge, could revert to the pseudobase form and also lose their charge at pH 7.4. Because the two amino groups in the aliphatic side chain of EHD are the most reactive, it is highly likely that either one of them could interact with the SMCC cross-linking reagent during the conjugation reaction and, therefore, lose its charge when an amide link is formed. Since the pK a of such amino groups is in the range of 9 -10, the remaining aliphatic amino group would be expected to retain its positive charge at physiologic pH of 7.4 and contribute a single positive charge to the MAb-EHD immunoconjugate. (3) MAb-EHD conjugate. As mentioned above, the conjugation of six to eight SPDP molecules per MAb leads to an overall loss of an equal number of positive charges. In addition, a single positive charge is contributed to each MAb molecule per EHD molecule conjugated. Since three to four EHD molecules were conjugated per MAb in our studies, the change in the antibody pI should therefore reflect an overall loss of three to four positive charges. The observed decrease of the MAb pI from 7.1 to 6.4 (Figs. 7 and 8) agrees with these expectations. Both the differences in the blood pharmacokinetics of 125 I-B72.3 and 125 I-B72.3(EHD) 3 (Table 1 ) and their biodistribution profiles (Figs. 9 and 10) appear, therefore, to be related to the decrease in pI of the EHD-labeled antibody, although it should be mentioned that changes in hydrophobicity due to conjugation of small molecules such as EHD may as well be responsible in part.
As mentioned earlier, tumor localization of the EHD-immunoconjugate was reduced severalfold compared with 125 I-B72.3 MAb. In normal tissues, however, both the uptake and retention differed (Figs. 9 and 10 ). For example, whereas the localization of the iodinated MAb within the liver was ϳ20% within the first few minutes after injection and declined rapidly with time, ϳ40% of the MAb-EHD conjugate activity was found in the liver by 1 min and the radioactivity increased to ϳ60% over the next 3 days. The altered pI may have led to the recognition and rapid uptake of the MAb by the reticuloendothelial system.
The results herein have confirmed that an in vitro immunoreactivity assay is not an indication of the in vivo behavior of immunoconjugates. They address the need for determining the extent of tumor targeting of immunoconjugates of drugs and toxins prior to their use in cancer therapy experiments. Owing to the limitations of immunoconjugate prepared by lysine-directed conjugation chemistry, it would be fortuitous to conjugate EHD to B72.3 MAb in a manner producing an immunoconjugate with unaltered pI that would target tumors efficiently (ϳ30% ID/g). We are presently exploring site-specific conjugation of EHD to the MAb via the carbohydrates of the F c region with the objective of overcoming the drawbacks in the current procedure and of developing pretargeting approaches for radioimmunotherapy. 
